id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-0944-0007,FDA,FDA-2014-E-0944,TECFIDERA-180 day letter,Other,Directors Determination,2018-04-13T04:00:00Z,2018,4,2018-04-13T04:00:00Z,,2018-04-13T17:07:20Z,,0,0,090000648313c23f
FDA-2014-E-0944-0006,FDA,FDA-2014-E-0944,"Determination of Regulatory Review Period for Purposes of Patent
Extension; TECFIDERA",Notice,Determinations,2017-10-05T04:00:00Z,2017,10,2017-10-05T04:00:00Z,2017-12-05T04:59:59Z,2017-10-05T14:44:55Z,2017-21435,0,0,0900006482ba018d
FDA-2014-E-0944-0005,FDA,FDA-2014-E-0944,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-06T04:00:00Z,2017,6,2017-06-06T04:00:00Z,,2017-06-06T13:17:54Z,,0,0,0900006482696b6e
FDA-2014-E-0944-0004,FDA,FDA-2014-E-0944,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2016-12-27T05:00:00Z,2016,12,2016-12-27T05:00:00Z,,2016-12-27T19:10:39Z,,0,0,09000064824384bf
FDA-2014-E-0944-0003,FDA,FDA-2014-E-0944,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-05T05:00:00Z,2015,11,2015-11-05T05:00:00Z,,2015-11-05T14:17:52Z,,0,0,0900006481d14812
FDA-2014-E-0944-0001,FDA,FDA-2014-E-0944,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2014-07-07T04:00:00Z,2014,7,2014-07-07T04:00:00Z,,2014-07-07T20:15:43Z,,0,0,0900006481794e75
FDA-2014-E-0944-0002,FDA,FDA-2014-E-0944,Patent Extension Application from Sterne Kessler Goldstein & Fox PLLC (Biogen Idec International GmbH),Other,Application,2014-07-07T04:00:00Z,2014,7,2014-07-07T04:00:00Z,,2014-07-07T20:15:50Z,,0,0,0900006481794e77